CytomX
CTMX
2.47
-0.09
-3.33%
CytomX
US · CTMX
#3678 by market cap
Listed 2015
2.47
-0.09
-3.33%
Live - 5344 symbols - heartbeat 209s ago
· 2026-10-08 10:11
Pre-market
2.62
+2.65%
After-hours
2.54
-0.39%
Overnight
2.63
+3.14%
- Market cap
- 537.12M
- P/E (TTM)i
- -4.32
- P/Bi
- 1.78
- EPSi
- -0.15
- Div yieldi
- 0.00%
- 52W posi
- 0%
Reader sentiment
Are you bullish or bearish on CTMX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.34, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -44.82% YoY
Margins
- Operating margin
- -29.35%
- Net margin
- -22.79%
Key ratios & quality
- Altman Z-Scorei
- 0.34
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 59.50M | 26.90M | 68.43M | 37.31M | 53.16M | 101.21M | 138.10M | 76.20M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 33.51M | 36.77M | 36.03M | 39.16M | 42.85M | 30.02M | 29.73M | 29.84M |
| Research & development | 103.87M | 131.62M | 112.94M | 114.19M | 111.65M | 77.68M | 83.38M | 68.73M |
| Operating profit | -77.87M | -141.48M | -80.54M | -116.04M | -101.34M | -6.48M | 25.00M | -22.36M |
| Pretax profit | -70.30M | -133.25M | -78.73M | -115.87M | -99.32M | 3.32M | 32.09M | -17.13M |
| Tax | 14.30M | -427.00K | -13.91M | 0 | 0 | 3.89M | 224.00K | 238.00K |
| Net profit | -84.60M | -132.83M | -64.82M | -115.87M | -99.32M | -569.00K | 31.87M | -17.37M |
| Basic EPS | -2 | -3 | -1 | -2 | -2 | 0 | 0 | 0 |
| Diluted EPS | -2.03 | -2.93 | -1.40 | -1.81 | -1.51 | -0.01 | 0.38 | -0.15 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 50.92M | 18.66M | 5.96M | 663.00K | 10.26M | 1.42M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 9.43M | 6.62M | 6.43M | 7.36M | 10.69M | 7.60M |
| Research & development | 18.87M | 13.32M | 15.30M | 21.24M | 19.24M | 17.60M |
| Operating profit | 22.62M | -1.29M | -15.77M | -27.93M | -19.67M | -23.78M |
| Pretax profit | 23.59M | -91.00K | -14.17M | -26.46M | -18.19M | -20.61M |
| Tax | 62.00K | 63.00K | 58.00K | 54.00K | 59.00K | 60.00K |
| Net profit | 23.53M | -154.00K | -14.23M | -26.51M | -18.25M | -20.67M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.27 | 0.00 | -0.09 | -0.22 | -0.10 | -0.09 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 445.48M | 303.34M | 324.01M | 310.30M | 237.10M | 182.94M | 107.31M | 143.92M |
| Cash & ST investments | 436.13M | 296.15M | 316.12M | 305.23M | 193.65M | 174.51M | 100.62M | 137.05M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 457.11M | 341.28M | 358.66M | 339.41M | 260.89M | 201.79M | 120.53M | 151.57M |
| Total current liabilities | 97.91M | 85.59M | 68.11M | 77.87M | 152.61M | 155.91M | 85.77M | 46.62M |
| Short-term debt | -- | 2.81M | 3.20M | 3.62M | 4.08M | 4.59M | 5.15M | 4.24M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 326,225,000.00 | 290,169,000.00 | 366,437,000.00 | 339,870,000.00 | 346,642,000.00 | 249,239,000.00 | 120,989,000.00 | 52,558,000.00 |
| Total equity | 130.88M | 51.11M | -7.77M | -459.00K | -85.75M | -47.45M | -456.00K | 99.01M |
| Retained earnings | -314.98M | -417.23M | -507.69M | -623.56M | -722.88M | -723.45M | -691.58M | -711.95M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 86.63M | 164.62M | 149.22M | 143.92M | 353.10M | 373.16M |
| Cash & ST investments | 79.89M | 158.09M | 143.63M | 137.05M | 346.71M | 330.28M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 98.50M | 175.06M | 158.25M | 151.57M | 359.36M | 381.23M |
| Total current liabilities | 50.20M | 39.22M | 41.03M | 46.62M | 34.02M | 39.86M |
| Short-term debt | 5.29M | 5.44M | 5.60M | 4.24M | 2.86M | 1.50M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 73,448,000.00 | 55,147,000.00 | 50,865,000.00 | 52,558,000.00 | 39,414,000.00 | 79,158,000.00 |
| Total equity | 25.05M | 119.91M | 107.39M | 99.01M | 319.94M | 302.07M |
| Retained earnings | -668.05M | -668.21M | -682.44M | -711.95M | -730.20M | -750.86M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -75.52M | -140.48M | 5.26M | -119.03M | -110.79M | -56.04M | -86.23M | -75.59M |
| Depreciation & amortization | 1.88M | 2.61M | 2.57M | 2.71M | 2.44M | 2.18M | 1.77M | 1.38M |
| Free cash flow | -79.31M | -143.98M | 2.95M | -120.64M | -112.53M | -56.88M | -86.54M | -75.81M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 134.60M | 0 | 11.29M | 107.71M | -- | -- | 6.91M | 109.64M |
| Ending cash balance | 248.49M | 189.34M | 192.78M | 206.45M | 194.57M | 18.09M | 39.08M | 14.19M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -21.04M | -15.75M | -15.55M | -23.24M | -25.55M | -18.07M |
| Depreciation & amortization | 385.00K | 347.00K | 134.00K | 510.00K | 251.00K | 47.00K |
| Free cash flow | -21.16M | -15.78M | -15.42M | -23.44M | -25.55M | -18.07M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 93.37M | 0 | 16.26M | 228.35M | 56.00K |
| Ending cash balance | 48.63M | 50.07M | 35.21M | 14.19M | 30.36M | 18.75M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -84.28 | -112.35 | -65.17 | -120.14 | -5,475.03 | -- | -- | -35.25 |
| ROA %i | -19.80 | -25.61 | -9.40 | -23.95 | -33.09 | -0.25 | 19.77 | -12.77 |
| ROIC %i | -89.83 | -93.17 | -44.54 | -90.31 | -465.85 | -- | -- | -38.30 |
| 5-year avg ROE %i | -- | -104.60 | -129.01 | -- | -- | -- | -- | -- |
| EBIT margin %i | -130.88 | -178.58 | -48.43 | -120.42 | -190.61 | -6.41 | 18.10 | -29.35 |
| FCF / sales %i | -- | -- | 2.94 | -- | -- | -- | -- | -- |
| Current ratioi | 4.55 | 3.54 | 4.76 | 3.98 | 1.55 | 1.17 | 1.25 | 3.09 |
| Quick ratioi | 4.46 | 3.46 | 4.65 | 3.93 | 1.50 | 1.14 | 1.21 | 2.98 |
| Debt / assetsi | 0.00 | 8.11 | 6.93 | 6.39 | 6.92 | 6.93 | 7.79 | 2.80 |
| LT debt / equityi | -- | 48.66 | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 97.60 | 21.38 | -1.51 | -14.41 | 25.49 | 13.94 | 54.69 | 12.75 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -74.05 | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | 108.21 | 66.76 | -35.25 | -34.29 | -37.75 |
| ROA %i | 29.38 | 28.71 | 18.85 | -12.77 | -25.83 | -28.64 |
| ROIC %i | -- | 79.96 | 46.06 | -38.30 | -35.45 | -38.79 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 24.37 | 30.56 | 20.46 | -29.35 | -181.92 | -476.17 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.73 | 4.20 | 3.64 | 3.09 | 10.38 | 9.36 |
| Quick ratioi | 1.63 | 4.08 | 3.54 | 2.98 | 10.21 | 9.23 |
| Debt / assetsi | 8.27 | 3.93 | 3.54 | 2.80 | 0.79 | 1.50 |
| LT debt / equityi | 11.40 | 1.20 | -- | -- | -- | 1.39 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 10:11:05 · For reference only, not investment advice and not tailored to your situation.